Yahoo
ASX - Delayed Quote AUD

Mayne Pharma Group Limited (MYX.AX)

2.5400 +0.0400 (+1.60%)
At close: October 30 at 4:10:11 PM GMT+11
Chart Range Bar
Loading chart for MYX.AX
  • Previous Close 2.5000
  • Open 2.5300
  • Bid 2.6600 x --
  • Ask 2.5500 x --
  • Day's Range 2.4750 - 2.5500
  • 52 Week Range 2.0400 - 6.0400
  • Volume 95,685
  • Avg. Volume 221,010
  • Market Cap (intraday) 208.003M
  • Beta (5Y Monthly) 1.02
  • PE Ratio (TTM) 8.19
  • EPS (TTM) 0.3100
  • Earnings Date (est.) --
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date Jan 18, 2023
  • 1y Target Est 4.37

Mayne Pharma Group Limited, a specialty pharmaceutical company, focuses on the commercialization of women's health and dermatology pharmaceuticals in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally. It operates through three segments: Women's Health, Dermatology, and International. The company provides oral drug delivery systems, as well as contract development and manufacturing services to third party customers. It also distributes specialty pharmaceutical products in the dermatology, women's health, and infectious disease areas. The company was formerly known as Halcygen Pharmaceuticals Limited and changed its name to Mayne Pharma Group Limited in November 2010. Mayne Pharma Group Limited was incorporated in 2005 and is based in Salisbury South, Australia.

www.maynepharma.com

363

Full Time Employees

June 30

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P/ASX 200 [XJO] (^AXJO) .

YTD Return

MYX.AX
18.33%
S&P/ASX 200 [XJO] (^AXJO)
2.22%

1-Year Return

MYX.AX
40.24%
S&P/ASX 200 [XJO] (^AXJO)
0.29%

3-Year Return

MYX.AX
30.79%
S&P/ASX 200 [XJO] (^AXJO)
31.37%

5-Year Return

MYX.AX
57.51%
S&P/ASX 200 [XJO] (^AXJO)
21.63%

Analyst Insights

View More

Analyst Price Targets

3.65
4.37 Average
2.5400 Current
5.25 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    6.38%

  • Return on Assets (ttm)

    -1.73%

  • Return on Equity (ttm)

    8.20%

  • Revenue (ttm)

    383.68M

  • Net Income Avi to Common (ttm)

    31.2M

  • Diluted EPS (ttm)

    0.3100

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    80M

  • Total Debt/Equity (mrq)

    11.05%

  • Levered Free Cash Flow (ttm)

    37.73M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: